Key Takeaways From argenx Analyst Ratings

Analysts' ratings for argenx ARGX over the last quarter vary from bullish to bearish, as provided by 10 analysts.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Analysts have set 12-month price targets for argenx, revealing an average target of $465.1, a high estimate of $522.00, and a low estimate of $402.00. Surpassing the previous average price target of $448.75, the current average has increased by 3.64%.

Interpreting Analyst Ratings: A Closer Look

In examining recent analyst actions, we gain insights into how financial experts perceive argenx. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to argenx. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of argenx compared to the broader market.
• Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of argenx's stock. This comparison reveals trends in analysts' expectations over time.

For valuable insights into argenx's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on argenx analyst ratings.

Get to Know argenx Better

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

Understanding the Numbers: argenx's Finances

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Growth: argenx's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 133.6%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: argenx's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -24.38%, the company may encounter challenges in effective cost control.

Return on Equity (ROE): argenx's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -2.42%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): argenx's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.18%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: argenx's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

What Are Analyst Ratings?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.